Agios Pharmaceuticals, Inc. - Rasio total nilai perusahaan marang pendapatan AGIO

Agios Pharmaceuticals management has pivoted its strategy toward rare genetic pathologies, divesting its oncology business to fund research and development. The GURU.Markets portal displays the EV/Sales multiple, where 7928.50 shows the current value of the metric. Revenues rely on sales of an anemia drug, creating a cash generator. However, high dependence on a narrow portfolio and pricing regulation in the US create certain risks.
Agios - rincian analitis lan metrik utama (AGIO)

This indicator compares the total enterprise value, adjusted for net debt, against annual sales to determine the asset's market premium. By analyzing the EV/Revenue multiple, an investor can see how the patents of Agios Pharmaceuticals (AGIO) in the field of rare genetic diseases allow the market to value the company with a high multiple premium due to the absence of direct competition.